PML/RARA t(15;17)(q22;q12) Gene Rearrangement Qualitative PCR Test in UAE

1,200 AED Next Tue/Thu/Sat Result

Executive Summary & Core Metrics

Diagnostic Precision: 99.9% sensitivity for detection of PML-RARA fusion transcript using ISO 15189 accredited real-time PCR methodology.
Turnaround Time: Results available on the next scheduled run day (Tuesday, Thursday, or Saturday) following sample collection.
Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM – 11 PM).
Clinical Guidance: Post-test teleconsultation with a DHA-licensed Consultant Medical Geneticist to interpret results and coordinate care.
Insurance: Direct verification of coverage via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The PML/RARA gene rearrangement qualitative PCR test is the gold‑standard molecular assay for the diagnosis and minimal residual disease monitoring of acute promyelocytic leukemia (APL). This test detects the PML-RARA fusion transcript resulting from the reciprocal translocation t(15;17)(q22;q12) using real‑time PCR (qPCR) with allele‑specific fluorescent probes, providing high sensitivity and specificity for the most common breakpoints (bcr1, bcr2, bcr3).

Feature	PML/RARA qPCR (This Test)	Alternative Methods
Target Detection	Fusion transcript (qualitative)	Karyotyping / FISH (chromosomal level)
Sensitivity	1 copy in 10⁵ cells (MRD-capable)	~5% (karyotyping) or ~1% (FISH)
Turnaround Time	Next Tue/Thu/Sat	7–10 days
Sample Requirement	Whole blood (EDTA) – 3 mL minimum	Bone marrow aspirate (for FISH/karyotyping)

Physician Insight & Safety Protocols

“As a Consultant Medical Geneticist with specialized training in hematological malignancies, I emphasize that a positive PML/RARA qualitative result should prompt urgent hematology‑oncology referral. A negative result does not rule out APL if clinical and morphological findings are suggestive; additional testing such as FISH or cytogenetics may be required. Always correlate molecular data with the complete blood count, coagulation profile, and bone marrow examination.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403

⚠️ Do not discontinue or alter any prescribed medication, including all‑trans retinoic acid (ATRA) or arsenic trioxide, without consulting your treating physician.

Exclusion Criteria & Emergency Red Flags

Sample hemolysis, clotting, or insufficient volume (< 3 mL whole blood in EDTA tube).
Incorrect tube type (non‑EDTA) or specimen exposed to freeze‑thaw cycles.
Transport delay > 48 hours at ambient temperature (requires cold chain < 8°C).
Seek immediate medical attention if: you experience sudden bruising, uncontrolled bleeding, fever with chills, or new‑onset shortness of breath — these may indicate APL‑related coagulopathy.

Patient FAQ & Clinical Guidance

1. What does a positive PML/RARA qualitative result mean for me?

A positive result indicates the presence of the PML-RARA fusion gene, which is diagnostic of acute promyelocytic leukemia (APL) in the appropriate clinical context. This requires urgent consultation with a hematologist‑oncologist for confirmatory testing and initiation of targeted therapy (e.g., ATRA and arsenic trioxide).

2. How should I prepare for the home blood collection?

No fasting is required. Please stay well hydrated and have your Emirates ID and a completed Genomics Clinical Information Requisition Form (Form 20) ready for the phlebotomist. Our mobile phlebotomy team will arrive with temperature‑controlled transport containers to ensure sample integrity.

3. Is my genetic data protected under UAE law?

Absolutely. All genomic data is processed in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Data is encrypted, access‑restricted, and never shared without your explicit consent.

4. Can this test be done during pregnancy?

If APL is suspected during pregnancy, the test can be performed on maternal peripheral blood. However, bone marrow aspiration may be deferred. Please discuss risks and benefits with your obstetrician and hematologist. Our team can coordinate same‑day collection with priority processing.

UAE Regulatory & Data Privacy Adherence

This test is performed under the regulatory framework of the Dubai Health Authority (DHA) and in accordance with:

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the processing, storage, and transfer of personal and genetic data.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – ensuring secure electronic health records and telemedicine compliance.
Federal Decree-Law No. 4 of 2016 on Medical Liability – upholding patient safety, informed consent, and clinical responsibility.

All results are reviewed and authorized by a DHA‑licensed Consultant Medical Geneticist (Lina Osama Zaki Quteineh, DHA #9294403) before release.

Clinical & Logistical Metadata

Test Name	PML/RARA t(15;17)(q22;q12) Gene Rearrangement Qualitative PCR
Price (AED)	1,200 AED
Turnaround Time	Next Tuesday, Thursday, or Saturday after sample collection (by 6:00 PM)
Sample Type / Matrix	Peripheral whole blood (EDTA) – 3 mL minimum; VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM – 11 PM
Methodology Used	Real‑Time PCR (qPCR) with allele‑specific fluorescent probes; detection of bcr1, bcr2, bcr3 breakpoints
ICD-10-CM Code	C92.50, Z15.09, C92.52
LOINC Code	43399-9
DHA Facility License & Address	License: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE